Javascript must be enabled to continue!
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
View through CrossRef
Abstract
Background
Routine prostate-specific membrane antigen (PSMA) positron emission tomography (PET) performed for primary staging or restaging of prostate cancer patients is usually done as a single static image acquisition 60 min after tracer administration. In this study, we employ dynamic whole-body (D-WB) PET imaging to compare the pharmacokinetics of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in various tissues and lesions, and to assess whether Patlak parametric images are quantitative and improve lesion detection and image readability.
Methods
Twenty male patients with prostate cancer were examined using a D-WB PSMA PET protocol. Ten patients were scanned with [68Ga]Ga-PSMA-11 and ten with [18F]PSMA-1007. Kinetic analyses were made using time-activity curves (TACs) extracted from organs (liver, spleen, bone, and muscle) and lesions. For each patient, three images were produced: SUV + Patlak parametric images (Ki and DV). All images were reviewed visually to compare lesion detection, image readability was quantified using target-to-background ratios (TBR), and Ki and DV values were compared.
Results
The two PSMA tracers exhibited markedly different pharmacokinetics in organs: reversible for [68Ga]Ga-PSMA-11 and irreversible for [18F]PSMA-1007. For both tracers, lesions kinetics were best described by an irreversible model. All parametric images were of good visual quality using both radiotracers. In general, Ki images were characterized by reduced vascular signal and increased lesion TBR compared with SUV images. No additional malignant lesions were identified on the parametric images.
Conclusion
D-WB PET/CT is feasible for both PSMA tracers allowing for direct reconstruction of parametric Ki images. The use of multiparametric PSMA images increased TBR but did not lead to the detection of more lesions. For quantitative whole-body Ki imaging, [18F]PSMA-1007 should be preferred over [68Ga]Ga-PSMA-11 due to its irreversible kinetics in organs and lesions.
Springer Science and Business Media LLC
Title: Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Description:
Abstract
Background
Routine prostate-specific membrane antigen (PSMA) positron emission tomography (PET) performed for primary staging or restaging of prostate cancer patients is usually done as a single static image acquisition 60 min after tracer administration.
In this study, we employ dynamic whole-body (D-WB) PET imaging to compare the pharmacokinetics of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in various tissues and lesions, and to assess whether Patlak parametric images are quantitative and improve lesion detection and image readability.
Methods
Twenty male patients with prostate cancer were examined using a D-WB PSMA PET protocol.
Ten patients were scanned with [68Ga]Ga-PSMA-11 and ten with [18F]PSMA-1007.
Kinetic analyses were made using time-activity curves (TACs) extracted from organs (liver, spleen, bone, and muscle) and lesions.
For each patient, three images were produced: SUV + Patlak parametric images (Ki and DV).
All images were reviewed visually to compare lesion detection, image readability was quantified using target-to-background ratios (TBR), and Ki and DV values were compared.
Results
The two PSMA tracers exhibited markedly different pharmacokinetics in organs: reversible for [68Ga]Ga-PSMA-11 and irreversible for [18F]PSMA-1007.
For both tracers, lesions kinetics were best described by an irreversible model.
All parametric images were of good visual quality using both radiotracers.
In general, Ki images were characterized by reduced vascular signal and increased lesion TBR compared with SUV images.
No additional malignant lesions were identified on the parametric images.
Conclusion
D-WB PET/CT is feasible for both PSMA tracers allowing for direct reconstruction of parametric Ki images.
The use of multiparametric PSMA images increased TBR but did not lead to the detection of more lesions.
For quantitative whole-body Ki imaging, [18F]PSMA-1007 should be preferred over [68Ga]Ga-PSMA-11 due to its irreversible kinetics in organs and lesions.
Related Results
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Abstract
Background
Differentiated thyroid carcinoma (DTC) is the most common type of thyroid cancer. Treatment with surgery, radioactive iodine (RAI), and TSH suppression is effec...
68Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters
68Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters
Background
Gliomas are the most common primary central nervous system tumors, of which the malignant gliomas account for 60%–75%. The primary and secondary brain malign...
Bridging bones
Bridging bones
Chapter 2 presents the evaluation of the feasibility of utilizing whole-body [18F]Fluoride PET/CT for visualizing molecular new bone formation in clinically active PsA patients. Th...
Abstract B054: Phase 1 study of 61Cu-NU101 in patients with prostate cancer
Abstract B054: Phase 1 study of 61Cu-NU101 in patients with prostate cancer
Abstract
Background:
Prostate Specific Membrane Antigen (PSMA)-targeted Positron Emission Tomography (PET) has revolution...
On Site Production of [18F]-PSMA1007 Using Different [18F]-fluoride Activities. Practical, Technical and Economical Impact.
On Site Production of [18F]-PSMA1007 Using Different [18F]-fluoride Activities. Practical, Technical and Economical Impact.
Abstract
BackgroundProstate-Specific Membrane Antigen is overexpressed in prostate cancer and it is considered a good target for staging of primary and recurrences as well ...
Clinical value of 18F-PSMA-1007 PET/MRI in primary staging of patients with intermediate- to high-risk prostate cancer
Clinical value of 18F-PSMA-1007 PET/MRI in primary staging of patients with intermediate- to high-risk prostate cancer
Abstract
Objective
To assess the utility of 18F-PSMA-1007 PET/MRI in initial staging of intermediate- to high-risk prostate canc...
SEMANA DE ENFERMAGEM E SEUS ASPECTOS SOCIAIS NA VALORIZAÇÃO PROFISSIONAL: UM RELATO DE EXPERIÊNCIA DO GRUPO PET-ENFERMAGEM
SEMANA DE ENFERMAGEM E SEUS ASPECTOS SOCIAIS NA VALORIZAÇÃO PROFISSIONAL: UM RELATO DE EXPERIÊNCIA DO GRUPO PET-ENFERMAGEM
A enfermagem é o pilar da assistência pois está na linha de frente do cuidado holístico, todavia esta é estigmatizada e desvalorizada, assim como não possui reconhecimento consider...
Head to Head Comparison of 18F-Fluorocholine and Imaging of Prostate-Specific Membrane Antigen, using 18F-DCFPyL PET/CT, in Patients with Biochemical Recurrence of Prostate Cancer: A Review
Head to Head Comparison of 18F-Fluorocholine and Imaging of Prostate-Specific Membrane Antigen, using 18F-DCFPyL PET/CT, in Patients with Biochemical Recurrence of Prostate Cancer: A Review
Purpose
To analyse diagnostic and therapeutic impact of molecular imaging TNM (miTNM) stage obtained with 18F-DCFPyL versus 18F-Fluorocholine in head to head comparison in bioche...

